Aurora Urges Shareholders to Reject Curaleaf's Hostile Bid, Citing $149M Cash vs $1B Debt
ACB sits 57% above its 52-week low of $2.56.
Summary
Aurora Cannabis filed a directors' circular unanimously recommending shareholders reject Curaleaf's hostile takeover bid, citing inadequate valuation, Curaleaf's $1B+ debt load, and weakened shareholder voting rights.
Key Events · M&A and Partnerships · ACB
-
Board Unanimously Rejects Hostile Bid
Aurora's board and special committee unanimously recommend shareholders reject Curaleaf's US$4.00 per share bid by taking no action and not tendering shares.
-
Balance Sheet Contrast
Aurora is debt-free with $149 million in cash as of June 30, 2026, while Curaleaf carries over $1 billion in debt — Aurora argues shareholders' cash would be used to fix Curaleaf's balance sheet.
-
Voting Power Dilution
Aurora shareholders would own approximately 7.7% of the combined company but hold only 3.2% of votes due to Curaleaf's multi-voting share structure.
-
Fairness Opinion
A written fairness opinion dated September 1, 2026 from Aurora's financial advisor concludes the bid undervalues Aurora; TD Securities analyst commentary supports this view.
Analysis · ACB · Life Sciences
Aurora's board unanimously recommends rejecting Curaleaf's US$4.00 per share hostile bid, arguing it significantly undervalues the company. The filing reveals Aurora is debt-free with $149 million in cash while Curaleaf carries over $1 billion in debt, and that Aurora shareholders would own only 7.7% of the combined company but hold just 3.2% of voting power. This is a critical escalation in the takeover battle, providing shareholders with concrete financial comparisons and governance concerns to justify rejection.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.